Preprint · 2023 · Open access

Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania

Jonathan J. Juliano, David Giesbrecht, Alfred Simkin, Abebe Alemu Fola, Beatus Modest Lyimo, Dativa Pereus, Catherine Bakari, Rashid A. Madebe, Misago D. Seth, Celine I. Mandara, Zachary R. Popkin-Hall, Ramadhan Moshi and 15 more

medRxiv · Published 8 November 2023 · DOI 10.1101/2023.11.07.23298207

Open PDFView at the publisherCite this paper

In brief

“Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania” is a 2023 preprint by Jonathan J. Juliano and 26 co-authors, published in medRxiv. OpenAlex counts 54 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at medRxiv.

Citations
54
Most cited in
2024 (20)
References
26
Authors
27

Abstract

Background Emergence of artemisinin partial resistance (ART-R) in Plasmodium falciparum is a growing threat to the efficacy of artemisinin combination therapies (ACT) and the efforts for malaria elimination. The emergence of Plasmodium falciparum Kelch13 (K13) R561H in Rwanda raised concern about the impact in neighboring Tanzania. In addition, regional concern over resistance affecting sulfadoxine-pyrimethamine (SP), which is used for chemoprevention strategies, is high. Methods To enhance longitudinal monitoring, the Molecular Surveillance of Malaria in Tanzania (MSMT) project was launched in 2020 with the goal of assessing and mapping antimalarial resistance. Community and clinic samples were assessed for resistance polymorphisms using a molecular inversion probe platform. Findings Genotyping of 6,278 samples collected countrywide in 2021 revealed a focus of K13 561H mutants in northwestern Tanzania (Kagera) with prevalence of 7.7% (50/649). A small number of 561H mutants (about 1%) were found as far as 800 km away in Tabora, Manyara, and Njombe. Genomic analysis suggests some of these parasites are highly related to isolates collected in Rwanda in 2015, supporting regional spread of 561H. However, a novel haplotype was also observed, likely indicating a second origin in the region. Other validated resistance polymorphisms (622I and 675V) were also identified. A focus of high sulfadoxine-pyrimethamine drug resistance was also identified in Kagera with a prevalence of dihydrofolate reductase 164L of 15% (80/526). Interpretation These findings demonstrate the K13 561H mutation is entrenched in the region and that multiple origins of ART-R, similar as to what was seen in Southeast Asia, have occurred. Mutations associated with high levels of SP resistance are increasing. These results raise concerns about the long-term efficacy of artemisinin and chemoprevention antimalarials in the region. Funding This study was funded by the Bill and Melinda Gates Foundation and the National Institutes of Health. Research in Context Evidence before this study We did a literature search via PubMed for research articles published from January 2014 to October 2023 using the search term “Africa” and “Artemisinin resistance” linked to “R561H” or “A675V” or “R622I”, returning 32 studies. The published literature shows the emergence and establishment of these three validated Plasmodium falciparum kelch13 (K13) mutations associated with artemisinin partial resistance (ART-R) in Africa. Large molecular studies of 675V in Uganda and 622I in Ethiopia have defined the regional spread of these mutations. However, limited data is available from recent studies about the spread and origins of the 561H mutation in the Great Lakes region of East Africa. In particular, detailed studies of the regions of Tanzania that border Rwanda have not been…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Juliano, J. J., Giesbrecht, D., Simkin, A., Fola, A. A., Lyimo, B. M., Pereus, D., Bakari, C., Madebe, R. A., Seth, M. D., Mandara, C. I., Popkin-Hall, Z. R., Moshi, R., Mbwambo, R. B., Niaré, K., MacInnis, B. L., Francis, F. T., Mbwambo, D., Garimo, I. A., Chacky, F., . . . Ishengoma, D. S. (2023). Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv. https://doi.org/10.1101/2023.11.07.23298207

MLA 9

Juliano, Jonathan J., et al. “Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania.” medRxiv, 2023. https://doi.org/10.1101/2023.11.07.23298207.

Chicago

Juliano, Jonathan J., David Giesbrecht, Alfred Simkin, Abebe Alemu Fola, Beatus Modest Lyimo, Dativa Pereus, Catherine Bakari, et al. 2023. “Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania.” medRxiv. https://doi.org/10.1101/2023.11.07.23298207.

Harvard

Juliano, J. J. et al. (2023) ‘Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania’, medRxiv. doi:10.1101/2023.11.07.23298207.

IEEE

J. J. Juliano et al., “Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania,” medRxiv, 2023, doi: 10.1101/2023.11.07.23298207.

BibTeX

@misc{juliano2023country,
  title     = {{Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania}},
  author    = {Juliano, Jonathan J. and Giesbrecht, David and Simkin, Alfred and Fola, Abebe Alemu and Lyimo, Beatus Modest and Pereus, Dativa and Bakari, Catherine and Madebe, Rashid A. and Seth, Misago D. and Mandara, Celine I. and Popkin-Hall, Zachary R. and Moshi, Ramadhan and Mbwambo, Ruth B. and Niaré, Karamoko and MacInnis, Bronwyn L. and Francis, Filbert T. and Mbwambo, Daniel and Garimo, Issa Ally and Chacky, Frank and Aaron, Sijenunu and Lusasi, Abdallah and Molteni, Fabrizio and Njau, Ritha and Lazaro, Samwel and Mohamed, Ally and Bailey, Jeffrey A. and Ishengoma, Deus S.},
  howpublished = {medRxiv},
  year      = {2023},
  doi       = {10.1101/2023.11.07.23298207},
  url       = {https://doi.org/10.1101/2023.11.07.23298207}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20242020
20251919
20261515

Topic and keywords

Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control

  • Plasmodium falciparum
  • sulfadoxine-pyrimethamine resistance
  • antimalarial drug resistance
  • molecular surveillance
  • haplotype diversity
  • artemisinin-based combination therapy
  • chemoprevention
  • Kagera

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Juliano, J. J., Giesbrecht, D., Simkin, A., Fola, A. A., Lyimo, B. M., Pereus, D., Bakari, C., Madebe, R. A., Seth, M. D., Mandara, C. I., Popkin-Hall, Z. R., Moshi, R., Mbwambo, R. B., Niaré, K., MacInnis, B. L., Francis, F. T., Mbwambo, D., Garimo, I. A., Chacky, F., . . . Ishengoma, D. S. (2023). Country wide surveillance reveals prevalent artemisinin partial resistance mutations with evidence for multiple origins and expansion of high level sulfadoxine-pyrimethamine resistance mutations in northwest Tanzania. medRxiv. https://doi.org/10.1101/2023.11.07.23298207

How many times has this paper been cited?

54 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at medRxiv: sign in and open the PDF from this page.

Who wrote this paper?

Jonathan J. Juliano, David Giesbrecht, Alfred Simkin, Abebe Alemu Fola, Beatus Modest Lyimo, Dativa Pereus, Catherine Bakari, Rashid A. Madebe, Misago D. Seth, Celine I. Mandara, Zachary R. Popkin-Hall, Ramadhan Moshi and 15 more.

What is the DOI of this paper?

10.1101/2023.11.07.23298207, permanently at https://doi.org/10.1101/2023.11.07.23298207. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.